AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops small molecule drug candidates for CNS diseases, focusing on Alzheimer’s disease and pain, today announced that another scientific article has been published on the phase I clinical results supporting the continued development of the lead drug candidate NeuroRestore ACD856. This compound is taken orally. It is being developed for Alzheimer’s disease; other potential indications include cognitive impairment due to Parkinson’s disease, traumatic brain injury, or sleep disorders and depression.
- Mechanism: Promoting the growth and survival of neurons is critical in neurodegenerative diseases. Drugs that boost brain-derived neurotrophic factor (BDNF) or similar neurotrophic molecules have shown promise in animal models. These compounds enhance neuronal plasticity and reduce neuron death, potentially slowing disease progression.
- Results: Animal studies have demonstrated significant cognitive improvements with these agents, with no major safety concerns observed.
- Current Stage: Several neurotrophic compounds are in preclinical stages.
https://www.alzforum.org/therapeutics/acd856